Viking Therapeutics (VKTX) Leases (2019 - 2025)
Viking Therapeutics' Leases history spans 7 years, with the latest figure at $85000.0 for Q4 2025.
- For Q4 2025, Leases fell 91.53% year-over-year to $85000.0; the TTM value through Dec 2025 reached $85000.0, down 91.53%, while the annual FY2025 figure was $85000.0, 91.53% down from the prior year.
- Leases for Q4 2025 was $85000.0 at Viking Therapeutics, down from $666000.0 in the prior quarter.
- Across five years, Leases topped out at $1.6 million in Q1 2022 and bottomed at $25000.0 in Q4 2021.
- The 5-year median for Leases is $1.0 million (2024), against an average of $908150.0.
- The largest annual shift saw Leases crashed 92.21% in 2021 before it surged 5572.0% in 2022.
- A 5-year view of Leases shows it stood at $25000.0 in 2021, then soared by 5572.0% to $1.4 million in 2022, then dropped by 20.59% to $1.1 million in 2023, then dropped by 10.92% to $1.0 million in 2024, then plummeted by 91.53% to $85000.0 in 2025.
- Per Business Quant, the three most recent readings for VKTX's Leases are $85000.0 (Q4 2025), $666000.0 (Q3 2025), and $780000.0 (Q2 2025).